NVIDIA and Bristol Myers Squibb (BMS) expanded their multi-year collaboration to deploy advanced AI supercomputing technology. BMS is constructing the life science industry’s most powerful AI factory using an NVIDIA DGX SuperPOD. This infrastructure features next-generation DGX Vera Rubin NVL72 systems.
The new platform delivers a tenfold increase in performance per megawatt compared to its predecessor. All BMS scientists will gain access to these tools to accelerate drug development in oncology and immunology. The initiative aims to compress discovery timelines and enhance the company's ability to create new medicines.